Due both to its potency versus other biologic agents, and the prolonged and consistent nature of its pharmacologic effects versus small molecule ferroportin inhibitors, REGN7999 is under further clinical development as a therapeutic for the treatment of iron overload in patients with non-transfusion-dependent β-thalassemia (NCT06421636) and other hematologic diseases. This evidence concerns the gene SLC40A1 and Tangier disease.